<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463501</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH09</org_study_id>
    <nct_id>NCT01463501</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer</brief_title>
  <official_title>Prospective Randomized Phase Ⅱ Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and Carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and Carboplatin) for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective Randomized Phase Ⅱ Trial Comparing Preoperative Chemoradiotherapy
      (Paclitaxel and carboplatin) Followed by Surgery to Surgery Followed by Postoperative
      Chemoradiotherapy (Paclitaxel and carboplatin) for Esophageal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Population:

      Thoracic esophageal cancer able to tolerate tri-modality therapy; Clinical stage T3-4, N0-1,
      M0

      Scheme:

      Patients are randomized to 2 arms:

      Arm A:

      Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate
      paclitaxel/carboplatin 2 cycles.

      Arm B:

      Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate
      paclitaxel/carboplatin 2 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores of Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the quality of life based on FACT-E.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the safety and tolerability based on NCI CTC V4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Three years disease free survival will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Three years overall survival will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative chemotherapy/radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative chemotherapy/radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neoadjuvant chemoradiotherapy</intervention_name>
    <description>Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.</description>
    <arm_group_label>Neoadjuvant Treatment</arm_group_label>
    <other_name>Neoadjuvant Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adjuvant chemoradiotherapy</intervention_name>
    <description>Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.</description>
    <arm_group_label>Adjuvant Treatment</arm_group_label>
    <other_name>Adjuvant Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic
             esophagus (&gt; 20cm from the incisors) or gastroesophageal junction are included.

          -  No distant metastases (M0).

          -  Patients will be stratified by stage (clinical N0 versus clinical N1).

          -  Patients with tumours within 3 cm distal spread into gastric cardia as detected by
             esophagogastroscopy.

          -  Resectable mediastinal nodes are eligible.

          -  No prior chemotherapy for this malignancy.

          -  No prior radiotherapy that would overlap the field(s) treated in this study.

          -  Patients with other malignancies are eligible only if &gt; 5 years without evidence of
             disease or completely resected or treated non-melanoma skin cancer.

          -  Age &gt; 18 years and able to tolerate tri-modality therapy at the discretion of the
             treating thoracic surgeon, medical and radiation oncologists. Tumours must be
             resectable after assessment by the thoracic surgeon.

        Exclusion Criteria:

          -  Cancers of the cervical esophagus (&lt; 20 cm are excluded).

          -  Tumours that have &gt; 3 cm of spread into cardia of the stomach are considered gastric
             cancers and are ineligible.

          -  Patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy ) proven
             metastatic supraclavicular nodes are ineligible.

          -  Patients with biopsy proven metastatic celiac nodes are ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weimin Mao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weimin Mao, MD.</last_name>
    <phone>+86-571-88122032</phone>
    <email>maowmzj1218@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Xu, MD.</last_name>
    <phone>+86-571-88122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weimin Mao, MD.</last_name>
      <phone>+86-571-88122032</phone>
      <email>maowmzj1218@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yaping Xu, MD</last_name>
      <phone>+86-571-88122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaping Xu, MD</last_name>
      <phone>+86 0571 88122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <last_update_submitted>May 11, 2013</last_update_submitted>
  <last_update_submitted_qc>May 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Resectable</keyword>
  <keyword>Neoadjuvant chemoradiotherapy</keyword>
  <keyword>Adjuvant chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

